Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Schneider, Christian KVleminckx, Camille
Gravanis, Iordanis
Ehmann, Falk
Trouvin, Jean-Hugues
Weise, Martina
Thirstrup, Steffen
Issue Date
2012-12
Metadata
Show full item recordCitation
Setting the stage for biosimilar monoclonal antibodies. 2012, 30 (12):1179-85 Nat. Biotechnol.Affiliation
Danish Health and Medicines Authority, Copenhagen, Denmark. c_schneid@web.deJournal
Nature biotechnologyDOI
10.1038/nbt.2447PubMed ID
23222783Type
ArticleLanguage
enISSN
1546-1696ae974a485f413a2113503eed53cd6c53
10.1038/nbt.2447
Scopus Count
The following license files are associated with this item:
Related articles
- Japanese regulation of biosimilar products: past experience and current challenges.
- Authors: Arato T
- Issue date: 2016 Jul
- Biopharmaceutical benchmarks 2018.
- Authors: Walsh G
- Issue date: 2018 Dec 6
- Interchangeability, immunogenicity and biosimilars.
- Authors: Ebbers HC, Crow SA, Vulto AG, Schellekens H
- Issue date: 2012 Dec
- Biosimilar regulation in the EU.
- Authors: Kurki P, Ekman N
- Issue date: 2015
- Monoclonal antibody: the corner stone of modern biotherapeutics.
- Authors: Xia ZN, Cai XT, Cao P
- Issue date: 2012 Oct